Rxsight Inc. is a cutting-edge healthcare technology company dedicated to transforming vision correction through advanced diagnostic and surgical solutions in refractive eye surgery. By integrating proprietary software with precision laser systems, Rxsight aims to significantly improve patient outcomes and enhance the quality of life for those seeking vision correction. The company boasts a robust intellectual property portfolio and strategic collaborations that position it favorably within the growing ophthalmic market. Committed to innovation and operational excellence, Rxsight is poised to drive substantial advancements in eye care, reflecting its potential for sustained growth and impact in the sector.
| Revenue (TTM) | $127.48M |
| Gross Profit (TTM) | $98.18M |
| EBITDA | $-52.02M |
| Operating Margin | -57.70% |
| Return on Equity | -17.10% |
| Return on Assets | -11.20% |
| Revenue/Share (TTM) | $3.10 |
| Book Value | $6.46 |
| Price-to-Book | 0.87 |
| Price-to-Sales (TTM) | 1.97 |
| EV/Revenue | 0.207 |
| EV/EBITDA | -7.70 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -18.50% |
| Shares Outstanding | $41.40M |
| Float | $39.09M |
| % Insiders | 6.45% |
| % Institutions | 93.26% |
Volatility is currently expanding
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALISO VIEJO, Calif., July 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on July 24, 2026, RxSight granted inducement stock options to purchase a total of 571,286 shares of RxSight's common stock and inducement restricted stock units (RSUs) covering a total of 2,312,138 shares of RxSight's common stock to Aziz Mottiwala, RxSight's new President and Chief Executive Officer in connection with his commencement of employment with RxSight.
RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ALISO VIEJO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who will continue to serve as Chief Medical Officer.
ALC is developing adjustable presbyopia-correcting lenses that pair advanced optics with post-surgery light adjustment.
RxSight, Inc. exhibits quantitative similarities to other small caps that I have rated here on Seeking Alpha that strongly outperformed the market. RXST is an 'NCAV' opportunity, a company that sells for less than its current asset value even though management is putting the company back on the growth track. My thesis is grounded in historical patterns where cash-rich, loss-making small caps often resolve operational issues before exhausting reserves.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) concerning whether the board breached its fiduciary duties to shareholders.IF YOU ARE A RXSIGHT, INC. (RXST) SHAREHOLDER, CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE.What Is The Investigation About?On July 8, 2025, after the market closed, RxSight reported preliminary second quarter.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) concerning whether the board breached its fiduciary duties to shareholders.IF YOU ARE A RXSIGHT, INC. (RXST) SHAREHOLDER, CLICK HERE TO PARTICIPATE.What Is The Investigation About?On July 8, 2025, after the market closed, RxSight reported preliminary second quarter 2025 financial results, revealing significant.
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RXST and any ticker you trade — then tracks every position and per-strategy win rate.
